

- ized with community-acquired pneumonia. *Arch Intern Med* 2007; 167:53–59.
7. **Nichol K, Nordin J, Nelson D, Mullooly J, Hak E.** Effectiveness of influenza vaccine in the community-dwelling elderly. *N Engl J Med* 2007; 357:1373–1381.
 8. **Madjid M, Miller C, Zarubaev V, et al.** Influenza epidemics and acute respiratory disease activity are associated with a surge in autopsy-confirmed coronary heart disease death: results from 8 years of autopsies in 34 892 subjects. *Eur Heart J* 2007; 28:1205–1210.
 9. **Keitel WA, Katmon RL, Cate TR, et al.** Safety of high doses of influenza vaccine and effect on antibody responses in elderly persons. *Arch Intern Med* 2006; 166:1121–1127.
 10. **King JC, Jr, Stoddard JJ, Gaglani MJ, et al.** Effectiveness of school-based influenza vaccination. *N Engl J Med* 2006; 355:2523–2532.
 11. **Belshe RB, Edwards KM, Vesikari T, et al.** Live attenuated versus inactivated influenza vaccine in infants and young children. *N Engl J Med* 2007; 356:685–696.
 12. **Vesikari T, Karvonen A, Korhonen T, et al.** A randomized, double-blind study of the safety, transmissibility and phenotypic and genotypic stability of cold-adapted influenza virus vaccine. *Pediatr Infect Dis J* 2006; 25:590–595.
 13. **Treanor JJ, Schiff GM, Hayden FG, et al.** Safety and immunogenicity of a baculovirus-expressed hemagglutinin influenza vaccine: a randomized controlled trial. *JAMA* 2007; 297:1577–1582.
 14. **Gerhard W, Mozdzanowska K, Zharikova D.** Prospects for universal influenza virus vaccine. *Emerg Infect Dis* 2006; 12:569–574.
 15. **US Centers for Disease Control and Prevention (CDC).** State-specific influenza vaccination coverage among adults aged ≥ 18 years—United States, 2003–04 and 2005–06 influenza seasons. *MMWR Morb Mortal Wkly Rep* 2007; 56:953–959.
 16. **Fiore AE, Shay DK, Haber P, et al; Advisory Committee on Immunization Practices (ACIP), Centers for Disease Control and Prevention (CDC).** Prevention and control of influenza. recommendations of the advisory committee on immunization practices (ACIP), 2007. *MMWR Recomm Rep* 2007; 56(RR-6):1–54.
 17. **Nichol KL.** Improving influenza vaccination rates among adults. *Cleve Clin J Med* 2006; 73:1009–1115.
 18. **Backer H.** Counterpoint: in favor of mandatory influenza vaccine for all health care workers. *Clin Infect Dis* 2006; 42:1144–1147.
 19. **Finch M.** Point: mandatory influenza vaccination for all health care workers? Seven reasons to say “no”. *Clin Infect Dis* 2006; 42:1141–1143.
 20. **Bertin M, Scarpelli M, Proctor AW, et al.** Novel use of the intranet to document health care personnel participation in a mandatory influenza vaccination reporting program. *Am J Infect Control* 2007; 35:33–37.
 21. **Schwartz B, Hinman A, Abramson J, et al.** Universal influenza vaccination in the United States: are we ready? Report of a meeting. *J Infect Dis* 2006; 194(suppl 2):S147–S154.
 22. **Falsey AR, Murata Y, Walsh EE.** Impact of rapid diagnosis on management of adults hospitalized with influenza. *Arch Intern Med* 2007; 167:354–360.
 23. **Carraro E, Neto DF, Benficia D, SittaPerosa AH, Granato CF, Bellei NC.** Applications of a duplex reverse transcription polymerase chain reaction and direct immunofluorescence assay in comparison with virus isolation for detection of influenza A and B. *Diagn Microbiol Infect Dis* 2007; 57:53–57.
 24. **Mossad SB.** Which agents should be used to treat and prevent influenza in 2006–2007? *Cleve Clin J Med* 2006; 73:1016–1018.
 25. **Deyde VM, Xu X, Bright RA, et al.** Surveillance of resistance to adamantanes among influenza A(H3N2) and A(H1N1) viruses isolated worldwide. *J Infect Dis* 2007; 196:249–257.
 26. **Kawai N, Ikematsu H, Iwaki N, et al.** A comparison of the effectiveness of oseltamivir for the treatment of influenza A and influenza B: a Japanese multicenter study of the 2003–2004 and 2004–2005 influenza seasons. *Clin Infect Dis* 2006; 43:439–444.
 27. **Hatakeyama S, Sugaya N, Ito M, et al.** Emergence of influenza B viruses with reduced sensitivity to neuraminidase inhibitors. *JAMA* 2007; 297:1435–1442.
 28. **Ong AK, Hayden FG.** John F. Enders Lecture 2006: Antivirals for influenza. *J Infect Dis* 2007; 196:181–190.
 29. **Maxwell SR.** Tamiflu and neuropsychiatric disturbance in adolescents. *BMJ* 2007; 334:1232–1233.
 30. **Webster RG, Govorkova EA.** H5N1 influenza—continuing evolution and spread. *N Engl J Med* 2006; 355:2174–2177.
 31. **Oner AF, Bay A, Arslan S, et al.** Avian influenza A (H5N1) infection in eastern Turkey in 2006. *N Engl J Med* 2006; 355:2179–2185.
 32. **Yang Y, Halloran M, Sugimoto JD, Longini Jr IM.** Detecting human-to-human transmission of avian influenza A (H5N1). *Emerg Infect Dis* 2007; 13:1348–1353.
 33. **Park AW, Glass K.** Dynamic patterns of avian and human influenza in east and southeast Asia. *Lancet Infect Dis* 2007; 7:543–548.
 34. **Murray CJ, Lopez AD, Chin B, Feehan D, Hill KH.** Estimation of potential global pandemic influenza mortality on the basis of vital registry data from the 1918–20 pandemic: a quantitative analysis. *Lancet* 2006; 368:2211–2218.
 35. **Markel H, Lipman HB, Navarro JA, et al.** Nonpharmaceutical interventions implemented by US cities during the 1918–1919 influenza pandemic. *JAMA* 2007; 298:644–654.
 36. **Luke TC, Kilbane EM, Jackson JL, Hoffman SL.** Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment? *Ann Intern Med* 2006; 145:599–609.
 37. **Sandbulte MR, Jimenez GS, Boon AC, Smith LR, Treanor JJ, Webby RJ.** Cross-reactive neuraminidase antibodies afford partial protection against H5N1 in mice and are present in unexposed humans. *PLoS Med* 2007; 4(2):e59.
 38. **Germann TC, Kadau K, Longini IM Jr, Macken CA.** Mitigation strategies for pandemic influenza in the United States. *Proc Natl Acad Sci U S A* 2006; 103:5935–5940.
 39. **Treanor JJ, Campbell JD, Zangwill KM, Rowe T, Wolff M.** Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. *N Engl J Med* 2006; 354:1343–1351.
 40. **Leroux-Roels I, Borkowski A, Vanwolleghem T, et al.** Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. *Lancet* 2007; 370:580–589.
 41. **Ortiz JR, Shay DK, Liedtke LA, Bresee JS, Strausbaugh LJ.** A national survey of the Infectious Diseases Society of America Emerging Infections Network concerning neuraminidase inhibitor prescription practices and pandemic influenza preparations. *Clin Infect Dis* 2006; 43:494–497.

ADDRESS: Sherif B. Mossad, MD, Department of Infectious Diseases, S32, Cleveland Clinic, 9500 Euclid Avenue, Cleveland OH, 44195; e-mail: mossads@ccf.org.

CORRECTION

In the review article “Ambulatory blood pressure monitoring: An argument for wider clinical use,” published in the November 2007 issue of the *Cleveland Clinic Journal of Medicine* (2007; 74:831–838), there

were two errors in the citation for the images in Figure 1. The images were provided by dabl Limited, Blackrock, Co. Dublin, Ireland. Their website address is www.dabl.ie.